林口算卦准的地方营口起名风水,济宁算命一条街在哪,大同算命准的人在哪,株洲哪里有算命先生算命灵验的,柏乡哪有算命准的,绥芬河人算命准吗,香港哪里有算卦的地方

SAN DIEGO (KGTV) - Holiday fun from around the world is coming to San Diego this season, as Global Winter Wonderland pops up at SDCCU Stadium.The multicultural theme park set up at the Mission Valley stadium features a circus of lights, a carnival, holiday-themed displays of locations around the world, an international food court, holiday shopping, and Santa (along with his trusty penguin, Penny.)RELATED: Southern California theme parks celebrate the holidays with festive eventsThe festival of holiday lights and music runs at the stadium on select dates from Nov. 11, 2017, to Jan. 7, 2018: 614

SAN DIEGO (KGTV) - Homeowners in La Mesa are being warned their houses could be at risk of a destructive pest: Formosan subterranean termites.San Diego-based company Thrasher Termite & Pest Control made the unfortunate discovery this month in a La Mesa home."Unlike native subterranean termites, the termites we observed were extremely active, didn't flee when disturbed, and the soldiers went into attack mode. They had hollowed out large areas of structural wood, always staying just beneath the exterior paint and unnoticed by the homeowner," said Garrett Thrasher.They're deemed "super-termites" due to enormous colonies up to two million strong. The pests can cause significant structural damage within six months unlike traditional dry-wood termites, which take 10-15 years to do similar damage.RELATED: Heat and humidity creating perfect conditions for bugsThe invasive species of termites was first discovered in La Mesa in 1992. Efforts to eradicate the population were thought to be successful, but pest control experts say that's no longer the case. Years after the discovery, monitoring efforts eventually stopped due to a lack of funding."They can't fly very far, but there's so many of them that they've continued to survive since the last sighting," said Thrasher.About 60 homeowners have received letters from San Diego County officials warning of potential risk.Thrasher says it's hard to say how large the problem is but he believes the pests have a strong foothold in the area.According to the University of California Agriculture and Natural Resources, the 1992 Formosan subterranean termite infestation was estimated to be about ten years old. This age corresponds to a time that a family living at the epicenter of the affected area brought wood and potted plants with them when they moved to La Mesa from Hawaii. Formosan subterranean termite is common in Hawaii; the species was misidentified for several years after its introduction in San Diego.RELATED: San Diegans report increase in mosquitoes during heat waveAs with virtually all species of termites, researchers say the hidden nature of young Formosan colonies make them especially difficult to detect and identify. Damage by young colonies is often localized and may go unnoticed for years.HOW CAN YOU TELL IF YOU HAVE FORMOSAN TERMITES?Check for what may look like paint chips around your windows or any wood area of your home. These may be hollowed-out areas created by termites.You can also check trees on your property for any obvious signs of termite; wood often appears to have been eaten away along the grain pattern.Another red flag is seeing swarmers; this is how they reproduce.WHAT CAN YOU DO IF YOU HAVE AN INFESTATION?Calling a pest control company is the first step. A professional will need to treat your home and create a chemical barrier. 2860

SAN DIEGO (KGTV) — Governor Gavin Newsom’s vaccine safety task force will have to work quickly once the FDA announces a decision on Pfizer’s COVID-19 vaccine candidate.The 11-member panel, officially called the Scientific Safety Review Workgroup, has been tasked with reviewing the safety and efficacy of vaccine trials and rendering a recommendation on their use in California.The workgroup has a difficult mission: review the data thoroughly enough to offer a recommendation independent from the FDA, but do it fast enough to avoid delaying distribution of the vaccine.Pfizer’s emergency use authorization application spans thousands of pages.The workgroup has already reviewed Pfizer’s early-stage clinical trial data from phases 1 and 2 and found no cause for concern, Governor Gavin Newsom said. They’re still waiting to get their hands on the all-important Phase 3 data, which included thousands of participants.Panel member Dr. Rodney Hood, the president of the Multicultural Health Foundation, acknowledged the task force will have to complete its review of the Phase 3 data “very, very quickly.” Dr. Hood is one of two members from the San Diego region, along with Dr. Mark Sawyer of Rady Children’s Hospital.“We certainly don't want to introduce any unnecessary delay in the vaccine being available to Californians,” Dr. Sawyer said.The FDA has scheduled a meeting of its vaccine advisory committee, known by its acronym VRBPAC (pronounced verb-pack), on Dec. 10. The agency said it will make Pfizer’s Phase 3 data available at least two days before that meeting.At the end of that meeting, a group of about 20 experts on the advisory committee will vote on whether to recommend emergency authorization of the vaccine. The FDA is expected to issue a decision shortly after, although the agency does not have to abide by the advisory committee’s recommendation.“The California committee is on notice to be ready for a meeting either later in the day on the 10th or on December 11,” said Dr. Sawyer.Dr. Sawyer was recently added to VRBPAC, so he will cast a vote on whether to recommend approval of the vaccine at the national level before participating in California’s process.“It is going to take a few days for the vaccine to really start flowing,” he said. “I don't think the [California] committee is going to introduce extra delay.”The California committee has promised to issue its decision within 24 hours of the FDA’s to avoid slowing down distribution, but that means the members may have as few as three days to review the safety and efficacy data.Federal regulators will spend about three weeks reviewing the thousands of pages of data submitted as part of Pfizer’s application. VRBPAC and the California Scientific Safety Review Workgroup will render decisions based on summaries prepared by the FDA, Dr. Sawyer said.Both doctors say they have confidence in the FDA’s process and acknowledge it would be very unlikely for the California workgroup to break with the agency’s recommendation. They said the mission of their review is to add an extra layer of verification after complaints the Trump administration was exercising political pressure on the FDA.“I think the governor foresaw that it was going to be very important that the general community accept these vaccines, assuming they're approved and are safe and effective, because otherwise we're not going to get out of this pandemic,” Dr. Sawyer said.The doctors say they want to make sure that community acceptance extends across all demographics, so they’ll be looking closely at the numbers to see if various ethnic or racial groups had different responses to the vaccine.Based on research on past vaccines, a differential response is not expected, Dr. Hood said. However, COVID-19 does strike Latinos and African-Americans more severely, making vaccine acceptance among minority communities all the more critical.“I want to look at the data, get an assessment of risk-benefit and the question I ask is, would I take it? Number one. Number two, if I would take it, would I recommend it to my family?” he said.The doctors said they will also closely examine reports of side effects.Early data suggests both Pfizer and Moderna’s candidates have somewhat harder-hitting side effects than the typical flu vaccine. Dr. Sawyer compared the side effects to the recent shingles vaccine.“Your arm hurts for a day or two. You may not feel well. You may feel a little bit under the weather for the first 24 hours. You could even have a mild fever or headache,” he said, noting those symptoms typically resolve within 24 to 48 hours based on the data available so far.“That's actually a good sign. You want that to happen,” he added.Those sorts of short-term side effects are signs the body is building a strong immune response. They’re evidence the vaccines work as well as advertised, but the doctors say they won’t know for certain until they review the final numbers. 4949

SAN DIEGO (KGTV) — Governor Gavin Newsom’s vaccine safety task force will have to work quickly once the FDA announces a decision on Pfizer’s COVID-19 vaccine candidate.The 11-member panel, officially called the Scientific Safety Review Workgroup, has been tasked with reviewing the safety and efficacy of vaccine trials and rendering a recommendation on their use in California.The workgroup has a difficult mission: review the data thoroughly enough to offer a recommendation independent from the FDA, but do it fast enough to avoid delaying distribution of the vaccine.Pfizer’s emergency use authorization application spans thousands of pages.The workgroup has already reviewed Pfizer’s early-stage clinical trial data from phases 1 and 2 and found no cause for concern, Governor Gavin Newsom said. They’re still waiting to get their hands on the all-important Phase 3 data, which included thousands of participants.Panel member Dr. Rodney Hood, the president of the Multicultural Health Foundation, acknowledged the task force will have to complete its review of the Phase 3 data “very, very quickly.” Dr. Hood is one of two members from the San Diego region, along with Dr. Mark Sawyer of Rady Children’s Hospital.“We certainly don't want to introduce any unnecessary delay in the vaccine being available to Californians,” Dr. Sawyer said.The FDA has scheduled a meeting of its vaccine advisory committee, known by its acronym VRBPAC (pronounced verb-pack), on Dec. 10. The agency said it will make Pfizer’s Phase 3 data available at least two days before that meeting.At the end of that meeting, a group of about 20 experts on the advisory committee will vote on whether to recommend emergency authorization of the vaccine. The FDA is expected to issue a decision shortly after, although the agency does not have to abide by the advisory committee’s recommendation.“The California committee is on notice to be ready for a meeting either later in the day on the 10th or on December 11,” said Dr. Sawyer.Dr. Sawyer was recently added to VRBPAC, so he will cast a vote on whether to recommend approval of the vaccine at the national level before participating in California’s process.“It is going to take a few days for the vaccine to really start flowing,” he said. “I don't think the [California] committee is going to introduce extra delay.”The California committee has promised to issue its decision within 24 hours of the FDA’s to avoid slowing down distribution, but that means the members may have as few as three days to review the safety and efficacy data.Federal regulators will spend about three weeks reviewing the thousands of pages of data submitted as part of Pfizer’s application. VRBPAC and the California Scientific Safety Review Workgroup will render decisions based on summaries prepared by the FDA, Dr. Sawyer said.Both doctors say they have confidence in the FDA’s process and acknowledge it would be very unlikely for the California workgroup to break with the agency’s recommendation. They said the mission of their review is to add an extra layer of verification after complaints the Trump administration was exercising political pressure on the FDA.“I think the governor foresaw that it was going to be very important that the general community accept these vaccines, assuming they're approved and are safe and effective, because otherwise we're not going to get out of this pandemic,” Dr. Sawyer said.The doctors say they want to make sure that community acceptance extends across all demographics, so they’ll be looking closely at the numbers to see if various ethnic or racial groups had different responses to the vaccine.Based on research on past vaccines, a differential response is not expected, Dr. Hood said. However, COVID-19 does strike Latinos and African-Americans more severely, making vaccine acceptance among minority communities all the more critical.“I want to look at the data, get an assessment of risk-benefit and the question I ask is, would I take it? Number one. Number two, if I would take it, would I recommend it to my family?” he said.The doctors said they will also closely examine reports of side effects.Early data suggests both Pfizer and Moderna’s candidates have somewhat harder-hitting side effects than the typical flu vaccine. Dr. Sawyer compared the side effects to the recent shingles vaccine.“Your arm hurts for a day or two. You may not feel well. You may feel a little bit under the weather for the first 24 hours. You could even have a mild fever or headache,” he said, noting those symptoms typically resolve within 24 to 48 hours based on the data available so far.“That's actually a good sign. You want that to happen,” he added.Those sorts of short-term side effects are signs the body is building a strong immune response. They’re evidence the vaccines work as well as advertised, but the doctors say they won’t know for certain until they review the final numbers. 4949

SAN DIEGO (KGTV) — For 10 days, San Diegans who enjoy the city's flair for craft beer will celebrate by, well, drinking beer.San Diego Beer Week showcases the county's more than 150 independent craft breweries from Nov. 1-10. Participating breweries host more than 500 events, including special tastings, food pairings, beer releases, and education sessions that introduce fans to new styles and even the brewers themselves.Beer Week officially kicks off during Guild Fest, which benefits the San Diego Brewers Guild and I Love A Clean San Diego. Attendees are treated to unlimited tasters from more than 60 San Diego County breweries. The week's end comes with a beer garden in Torrey Pines featuring beers paired with delicious eats by local chefs.RELATED: Proposed food hall, beer garden aims to transform National CityThe week will also see the release of a special "2019 Capital of Craft IPA," a 7.3% west coast-style IPA that's brewed and bottled for release throughout the county. According to the Brewers Guild, this year's recipe was a collaboration between eight local breweries.Drinkers can easily find events and breweries by visiting the SDBW website here or downloading the "SDBeer" mobile app, which compiles San Diego's craft breweries, events, and profiles year-round.To help attendees travel safely, Lyft has partnered with SDBW by offering two 20% discounts to and from any event using the code "SDBW19" in the mobile app.San Diego beer facts: San Diego's love for beer goes beyond special beers and parties. As the Guild points out, craft beer has become a staple industry in San Diego, providing .2 billion in economic impact and boasting about 8 million in revenue. Since 2016, craft beer's economic impact has climbed 34%.Confidence in beer is also high, according to a recent report. San Diego's craft beer confidence index sat at 91, which includes how experts feel about barrelage production, distribution, employment, and capital expenditures.The majority of San Diego's breweries sit in central San Diego, where drinkers can find 55% of the county's brewers. North County hosts the next largest percentage with 32.5% of breweries, followed by East County with 8.1%, and the South Bay with 4.4%.But those percentages could change, as the South Bay pushes for more breweries as part of the "South Bay Uprising" campaign.California has the highest number of craft breweries in the U.S., with more than 900 breweries as of January 2019. Those breweries produced about 3.4 million barrels of beer in 2018.And while we don't exactly know what San Diego drinkers favor, nationwide, IPAs lead with 25.2% of the market share. Belgian white brews command 20.6% of the market, followed by other styles (14.5%), seasonal beers (13.6%), and lagers (11.1%), the report above suggests. Pale ales, fruit, and amber ale beers made up the rest of the country's segmentation. 2897